Monitoring of Adverse Event for Anticancer Drugs Using Mobile Healthcare

Monitoring of Adverse Event for Anticancer Drugs Using Mobile Healthcare - Monitoring of Adverse Event for Anticancer Drugs Using Mobile Healthcare

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052672

Enrollment

Registered

2023-12-01

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancers

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with pathologically diagnosed cancer 2. patients who are scheduled to receive anticancer drug treatment 3. patients who are expected to have a prognosis of at least 6 months 4. patients whose consent to participate in this study has been obtained by signing a consent form by the patient himself/herself

Exclusion criteria

Exclusion criteria: 1. patients who have received no anticancer therapy but only supportive or palliative therapy 2. patients with a prognosis predicted to be less than 6 months

Design outcomes

Primary

Measure	Time frame
Detection rate of adverse events of anticancer therapy by mobile healthcare	—

Countries

Japan

Contacts

Public ContactMasato Karayama

Hamamatsu University School of Medicine Cancer Center

karayama@hama-med.ac.jp053-435-2491

Outcome results